Vigonvita Life Sciences Announces Current Board Line-up and Committee Assignments

Bulletin Express06-30

Vigonvita Life Sciences Co., Ltd. released an updated roster of its Board of Directors, confirming six members and detailing their roles across three specialised committees.

The Board now comprises two executive directors—Dr. Tian Guanghui and Dr. Hu Tianwen—one non-executive director, Mr. Liu Haoxuan, and three independent non-executive directors: Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.

Committee structures are as follows: 1. Audit Committee: chaired by independent director Ms. Cao Xinwen, with Dr. Ju Dianwen and Dr. Xu Hongxi serving as members. 2. Remuneration and Appraisal Committee: chaired by Dr. Xu Hongxi; membership includes Dr. Hu Tianwen and Ms. Cao Xinwen. 3. Nomination Committee: chaired by executive director Dr. Tian Guanghui, joined by Dr. Ju Dianwen and Dr. Xu Hongxi as members.

The announcement, dated 30 June 2026 in Hong Kong, aligns governance responsibilities with regulatory best practices by ensuring independent directors hold chair positions in two of the three key committees, thereby reinforcing oversight and accountability within Vigonvita’s corporate structure.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113335976?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 22:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113335976","market":"hk","top_or_hot":-1,"title":"Vigonvita Life Sciences Announces Current Board Line-up and Committee Assignments","media":"Bulletin Express","content":"<p>Vigonvita Life Sciences Co., Ltd. released an updated roster of its Board of Directors, confirming six members and detailing their roles across three specialised committees.</p>\n<p>The Board now comprises two executive directors—Dr. Tian Guanghui and Dr. Hu Tianwen—one non-executive director, Mr. Liu Haoxuan, and three independent non-executive directors: Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.</p>\n<p>Committee structures are as follows:  \n1. Audit Committee: chaired by independent director Ms. Cao Xinwen, with Dr. Ju Dianwen and Dr. Xu Hongxi serving as members.  \n2. Remuneration and Appraisal Committee: chaired by Dr. Xu Hongxi; membership includes Dr. Hu Tianwen and Ms. Cao Xinwen.  \n3. Nomination Committee: chaired by executive director Dr. Tian Guanghui, joined by Dr. Ju Dianwen and Dr. Xu Hongxi as members.</p>\n<p>The announcement, dated 30 June 2026 in Hong Kong, aligns governance responsibilities with regulatory best practices by ensuring independent directors hold chair positions in two of the three key committees, thereby reinforcing oversight and accountability within Vigonvita’s corporate structure.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences Announces Current Board Line-up and Committee Assignments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences Announces Current Board Line-up and Committee Assignments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-30 22:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vigonvita Life Sciences Co., Ltd. released an updated roster of its Board of Directors, confirming six members and detailing their roles across three specialised committees.</p>\n<p>The Board now comprises two executive directors—Dr. Tian Guanghui and Dr. Hu Tianwen—one non-executive director, Mr. Liu Haoxuan, and three independent non-executive directors: Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.</p>\n<p>Committee structures are as follows:  \n1. Audit Committee: chaired by independent director Ms. Cao Xinwen, with Dr. Ju Dianwen and Dr. Xu Hongxi serving as members.  \n2. Remuneration and Appraisal Committee: chaired by Dr. Xu Hongxi; membership includes Dr. Hu Tianwen and Ms. Cao Xinwen.  \n3. Nomination Committee: chaired by executive director Dr. Tian Guanghui, joined by Dr. Ju Dianwen and Dr. Xu Hongxi as members.</p>\n<p>The announcement, dated 30 June 2026 in Hong Kong, aligns governance responsibilities with regulatory best practices by ensuring independent directors hold chair positions in two of the three key committees, thereby reinforcing oversight and accountability within Vigonvita’s corporate structure.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1113335976","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113335976","pubTimestamp":1782829479,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Vigonvita Life Sciences Co., Ltd. released an updated roster of its Board of Directors, confirming six members and detailing their roles across three specialised committees. The Board now comprises...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"Vigonvita Life Sciences宣布当前董事会阵容和委员会任务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences Co., Ltd. released an updated roster of its Board of Directors, confirming six members and detailing their roles across three specialised committees.\nThe Board now comprises two executive directors—Dr. Tian Guanghui and Dr. Hu Tianwen—one non-executive director, Mr. Liu Haoxuan, and three independent non-executive directors: Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi.\nCommittee structures are as follows:  \n1. Audit Committee: chaired by independent director Ms. Cao Xinwen, with Dr. Ju Dianwen and Dr. Xu Hongxi serving as members.  \n2. Remuneration and Appraisal Committee: chaired by Dr. Xu Hongxi; membership includes Dr. Hu Tianwen and Ms. Cao Xinwen.  \n3. Nomination Committee: chaired by executive director Dr. Tian Guanghui, joined by Dr. Ju Dianwen and Dr. Xu Hongxi as members.\nThe announcement, dated 30 June 2026 in Hong Kong, aligns governance responsibilities with regulatory best practices by ensuring independent directors hold chair positions in two of the three key committees, thereby reinforcing oversight and accountability within Vigonvita’s corporate structure.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113335976","isCrawlerRequest":true}